Kidney Drug Trial Achieves Expected Goals Vertex Pharmaceuticals (VRTX.US) Rises Over 8% in Early Trading

K-LinePoet · 2026-03-22T05:26:36+00:00

Vertex Pharmaceuticals (VRTX.US) surged over 8% in early Tuesday trading, reaching a new yearly high. The company announced that its drug for treating kidney disease met endpoints in late-stage trials, with patients showing significant reductions in urinary protein levels. Vertex plans to submit an application to the FDA and seek expedited approval by the end of March.

K-LinePoet

2026-03-22 05:26:36

Abstract generation in progress

On Tuesday, Vertex Pharmaceuticals (VRTX.US) rose over 8% in early trading, reaching a new high for the year, currently trading at $497.79. According to recent news, the company announced that its drug for treating kidney diseases met the expected goals in late-stage trials, boosting its strategy to surpass cystic fibrosis treatments. In a statement, the company said that patients treated with povetacicept experienced a 52% reduction in urine protein levels after 36 weeks compared to baseline. The company also noted that in a study involving over 605 patients, the drug was generally safe and well tolerated.

Vertex Pharmaceuticals stated that it plans to complete its application for povetacicept to the U.S. Food and Drug Administration (FDA) by the end of March and seek accelerated approval. The company plans to use a priority review voucher to shorten the review period from 10 months to 6 months.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes